EUR 2.81
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 16.73 Million EUR | 1831.43% |
2022 | 930.96 Thousand EUR | 9.73% |
2021 | 848.38 Thousand EUR | -3.46% |
2020 | 878.79 Thousand EUR | -90.11% |
2019 | 8.88 Million EUR | 12.62% |
2018 | 7.89 Million EUR | 49.08% |
2017 | 5.29 Million EUR | -12.53% |
2016 | 6.05 Million EUR | 6.73% |
2015 | 5.66 Million EUR | 5.65% |
2014 | 5.36 Million EUR | 8.94% |
2013 | 4.92 Million EUR | -37.89% |
2012 | 7.93 Million EUR | 19.96% |
2011 | 6.61 Million EUR | 138.09% |
2010 | 2.77 Million EUR | 36.72% |
2009 | 2.03 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 10.01 Million EUR | 0.0% |
2023 FY | 17.98 Million EUR | 1831.43% |
2023 Q2 | 500.53 Thousand EUR | 0.0% |
2023 Q4 | 17.84 Million EUR | 0.0% |
2022 FY | 930.96 Thousand EUR | 9.73% |
2022 Q4 | 366.63 Thousand EUR | 0.0% |
2022 Q2 | 564.33 Thousand EUR | 0.0% |
2021 Q4 | 416.68 Thousand EUR | 0.0% |
2021 FY | 848.38 Thousand EUR | -3.46% |
2021 Q2 | 431.69 Thousand EUR | 0.0% |
2020 Q2 | 363.08 Thousand EUR | 0.0% |
2020 Q4 | 515.71 Thousand EUR | 0.0% |
2020 FY | 878.79 Thousand EUR | -90.11% |
2019 Q2 | 4.18 Million EUR | 0.0% |
2019 Q4 | 290.16 Thousand EUR | 0.0% |
2019 FY | 8.88 Million EUR | 12.62% |
2018 Q2 | 3.85 Million EUR | 0.0% |
2018 FY | 7.89 Million EUR | 49.08% |
2018 Q4 | 4.03 Million EUR | 0.0% |
2017 Q2 | 2.29 Million EUR | 0.0% |
2017 FY | 5.29 Million EUR | -12.53% |
2017 Q4 | 2.8 Million EUR | 0.0% |
2016 Q4 | 3.36 Million EUR | 0.0% |
2016 Q2 | 2.68 Million EUR | 0.0% |
2016 FY | 6.05 Million EUR | 6.73% |
2015 Q2 | 2.77 Million EUR | 0.0% |
2015 Q4 | 2.89 Million EUR | 0.0% |
2015 FY | 5.66 Million EUR | 5.65% |
2014 Q4 | 2.66 Million EUR | 0.0% |
2014 FY | 5.36 Million EUR | 8.94% |
2014 Q2 | 2.7 Million EUR | 0.0% |
2013 Q2 | 2.49 Million EUR | 0.0% |
2013 Q4 | 2.43 Million EUR | 0.0% |
2013 FY | 4.92 Million EUR | -37.89% |
2012 Q3 | 347.59 Thousand EUR | 0.0% |
2012 Q1 | 347.59 Thousand EUR | 0.0% |
2012 Q4 | 401.77 Thousand EUR | 15.59% |
2012 FY | 7.93 Million EUR | 19.96% |
2012 Q2 | 347.59 Thousand EUR | 0.0% |
2011 Q3 | 105.69 Thousand EUR | 0.0% |
2011 FY | 6.61 Million EUR | 138.09% |
2011 Q4 | 347.59 Thousand EUR | 228.87% |
2011 Q2 | 105.69 Thousand EUR | 0.0% |
2011 Q1 | 105.69 Thousand EUR | 0.0% |
2010 Q1 | 132.41 Thousand EUR | 0.0% |
2010 Q4 | 105.69 Thousand EUR | -20.18% |
2010 FY | 2.77 Million EUR | 36.72% |
2010 Q3 | 132.41 Thousand EUR | 0.0% |
2010 Q2 | 132.41 Thousand EUR | 0.0% |
2009 FY | 2.03 Million EUR | 0.0% |
2009 Q1 | 73.54 Thousand EUR | 0.0% |
2009 Q4 | 132.41 Thousand EUR | 80.06% |
2009 Q3 | 73.54 Thousand EUR | 0.0% |
2009 Q2 | 73.54 Thousand EUR | 0.0% |
2008 Q4 | 73.54 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -300.725% |
ABIVAX Société Anonyme | 127.37 Million EUR | 86.859% |
Adocia SA | 15.62 Million EUR | -7.098% |
Aelis Farma SA | 18.81 Million EUR | 11.056% |
Biophytis S.A. | 14.33 Million EUR | -16.781% |
Advicenne S.A. | 8.21 Million EUR | -103.753% |
IntegraGen SA | 5.35 Million EUR | -212.718% |
Medesis Pharma S.A. | 1.56 Million EUR | -969.832% |
Neovacs S.A. | 10.34 Million EUR | -61.823% |
NFL Biosciences SA | 4.37 Million EUR | -282.646% |
Plant Advanced Technologies SA | 2.76 Million EUR | -505.396% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -874.309% |
Sensorion SA | 27.05 Million EUR | 38.129% |
Theranexus Société Anonyme | 3 Million EUR | -457.017% |
TME Pharma N.V. | 5.49 Million EUR | -204.499% |
Valbiotis SA | 9.86 Million EUR | -69.605% |
TheraVet SA | 1.64 Million EUR | -917.95% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 17.627% |
DBV Technologies S.A. | 89.4 Million EUR | 81.278% |
Genfit S.A. | 54.8 Million EUR | 69.458% |
GeNeuro SA | 14.35 Million EUR | -16.584% |
Innate Pharma S.A. | 64.57 Million EUR | 74.077% |
Inventiva S.A. | 120.18 Million EUR | 86.073% |
MaaT Pharma SA | 21.59 Million EUR | 22.501% |
MedinCell S.A. | 32.92 Million EUR | 49.158% |
Nanobiotix S.A. | 58.92 Million EUR | 71.595% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 29.042% |
Poxel S.A. | 28.76 Million EUR | 41.81% |
GenSight Biologics S.A. | 32.66 Million EUR | 48.75% |
Transgene SA | 31.23 Million EUR | 46.405% |
Valneva SE | 134.92 Million EUR | 87.594% |